Brighton Jones LLC Purchases 3,083 Shares of STERIS plc $STE

Brighton Jones LLC boosted its position in shares of STERIS plc (NYSE:STE) by 218.0% in the 3rd quarter, HoldingsChannel reports. The firm owned 4,497 shares of the medical equipment provider’s stock after buying an additional 3,083 shares during the period. Brighton Jones LLC’s holdings in STERIS were worth $1,113,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Spurstone Advisory Services LLC bought a new stake in STERIS during the second quarter worth about $29,000. Geneos Wealth Management Inc. boosted its holdings in shares of STERIS by 416.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 104 shares in the last quarter. Loomis Sayles & Co. L P bought a new stake in STERIS during the 2nd quarter worth approximately $54,000. Generali Investments Management Co LLC bought a new stake in STERIS during the 2nd quarter worth approximately $56,000. Finally, CYBER HORNET ETFs LLC acquired a new stake in STERIS during the 2nd quarter valued at $62,000. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, VP Renato Tamaro sold 5,036 shares of the company’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $257.55, for a total value of $1,297,021.80. Following the sale, the vice president directly owned 5,695 shares of the company’s stock, valued at approximately $1,466,747.25. This represents a 46.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP John Adam Zangerle sold 15,000 shares of STERIS stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $265.14, for a total value of $3,977,100.00. Following the transaction, the vice president owned 33,669 shares of the company’s stock, valued at $8,926,998.66. The trade was a 30.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 25,203 shares of company stock valued at $6,624,667 in the last 90 days. 1.07% of the stock is owned by company insiders.

STERIS Stock Up 0.1%

Shares of NYSE STE opened at $255.68 on Thursday. STERIS plc has a 52-week low of $200.98 and a 52-week high of $268.60. The stock has a market cap of $25.09 billion, a P/E ratio of 36.74 and a beta of 1.01. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.63 and a current ratio of 2.37. The firm has a 50 day moving average price of $253.68 and a 200 day moving average price of $244.40.

STERIS (NYSE:STE) last posted its earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.38 by $0.09. STERIS had a return on equity of 14.43% and a net margin of 12.07%.The business had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.43 billion. During the same period in the prior year, the business earned $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. Analysts expect that STERIS plc will post 9.08 EPS for the current year.

STERIS Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, December 18th. Shareholders of record on Tuesday, November 18th were paid a $0.63 dividend. The ex-dividend date was Tuesday, November 18th. This represents a $2.52 dividend on an annualized basis and a yield of 1.0%. STERIS’s dividend payout ratio (DPR) is currently 36.21%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Wall Street Zen raised STERIS from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 14th. Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a research report on Tuesday, October 14th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $273.50.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.